Skip to content

Robotic Rehabilitation and Brain Stimulation for Children With Hemiparetic Cerebral Palsy

Robotic Rehabilitation and Brain Stimulation for Children With Hemiparetic Cerebral Palsy

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04233710
Acronym
RoboCP
Enrollment
20
Registered
2020-01-18
Start date
2019-03-25
Completion date
2021-12-31
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemiplegic Cerebral Palsy, Perinatal Stroke

Keywords

robotic rehabilitation, tDCS, non-invasive brain stimulation

Brief summary

This study evaluates the use of robotic rehabilitation with and without transcranial direct current stimulation (tDCS) to improve motor performance in children with hemiparetic cerebral palsy. Half of the participants will receive robotic rehabilitation and half will receive robotic rehabilitation with tDCS. We hypothesize that tDCS may augment the robotic therapy and show greater improvements than robotic therapy alone.

Detailed description

The defining feature of hemiparetic cerebral palsy is motor impairments primarily on one side of the body. Robotic rehabilitation and non-invasive brain stimulation are both emerging technologies that may be beneficial in improving motor performance in individuals with hemiparetic cerebral palsy. Robotic rehabilitation can allow for hundreds of arm movements in the span of an hour, a level of concentrated repetitions that is not possible in traditional rehabilitation. Additionally, robotics can target specific deficits, such as coordinating both arms together, improving accuracy of reaching movements, or improving proprioception, while simultaneously giving the therapist and patient quantitative feedback on performance. Non-invasive brain stimulation using transcranial direct current stimulation (tDCS) can safely modulate activity in regions of the brain and has emerged as a tool to enhance motor learning in typically developing children and augment therapy in children with hemiparetic cerebral palsy. Children with hemiparetic cerebral palsy will be randomized to receive robotic rehabilitation with tDCS or robotic rehabilitation with sham-tDCS. Participants and the assessors will be blinded to the treatment. All children will complete 10 sessions within 3 weeks of 1.5 hours of robotic rehabilitation. The Kinarm Exoskeleton Robot will be used and children will play games with their affected arm or both arms to target different aspects of sensorimotor control. Children will simultaneously receive real or sham tDCS for the first 20 minutes of the session. tDCS will consist of 1 mA current with the cathode applied over the contralesional M1 area. All children will be assessed before and after the 10 session intervention period using robotic and clinical measures of motor and sensory performance, and at a 3 month follow up.

Interventions

COMBINATION_PRODUCTRobot Rehabilitation + tDCS

Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.

BEHAVIORALRobotic Rehabilitation + sham tDCS

Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* confirmed diagnosis of hemiparetic cerebral palsy due to unilateral perinatal stroke * age 6-18 years * Manual Ability Classification System (MACS) Level I-III * Modified Ashworth Score in shoulder and elbow \<=3; * Visual acuity (corrected) better than 20/50 in both eyes * able to follow instructions and comply with protocol; * able to give consent/assent; * able to commit to all assessment and intervention sessions.

Exclusion criteria

* significant contractures in the upper extremity; * other neurological conditions or active medical disease; * unstable epilepsy; * contraindications to tDCS; * botulinum toxin A injections in the upper extremity in the past 6 months; * upper extremity surgical intervention in past 6 months; * involvement in another interventional study.

Design outcomes

Primary

MeasureTime frameDescription
Reaching Accuracychange between pre-assessment (within 1 week of starting intervention) and post-assessment (within 1 week of completing intervention)Change in reaching accuracy as measured by initial direction error on robotic visually guided reaching task.

Secondary

MeasureTime frameDescription
Standardized robotic measures of motor and sensory performancechange between pre-assessment (within 1 week of starting intervention) and post-assessment (within 1 week of completing intervention)Robotic measures of spatiotemporal reaching (path length ratio, reaction time, movement speed, number of speed maximums), proprioception (variability in position matching) and bilateral object hitting task (number of balls hit with each hand). Each measure will be assessed as change from pre-assessment to immediate post-assessment
Assisting Hand Assessmentchange between pre-assessment (within 1 week of starting intervention) and post-assessment (within 1 week of completing intervention)Performance on clinical assessment that determines how effectively the affected limb is used on tasks typically requiring both arms.
Box and Block Assessmentchange between pre-assessment (within 1 week of starting intervention) and post-assessment (within 1 week of completing intervention)Measure of ability to reach, grasp and release that measures how many 1 cubes a child can move from one side of a box to another in 1 minute.
Purdue Pegboardchange between pre-assessment (within 1 week of starting intervention) and post-assessment (within 1 week of completing intervention)Measure of manual dexterity measured by how many small pegs a child can place in a pegboard in 30 seconds.

Countries

Canada

Contacts

Primary ContactRachel L Hawe, DPT, PhD
rachel.hawe@ucalgary.ca403-944-1094
Backup ContactSean P Dukelow, MD, PhD
spdukelo@ucalgary.ca403-944-5930

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026